In addition to patient profile, therapy for patients with acute myeloid leukaemia is guided by their molecular and cytogenetic profile. Mutations in FLT3 gene is one of the most frequently encountered and clinically challenging class of AML mutations. Though many small molecule inhibitors targeting FLT3 are in clinical development, only a few could provide successful remission in clinical setting.
Approval of Rydapt as the only approved targeted therapy brings therapeutic promise to patients who are newly diagnosed with FLT3-AML as well as with advanced systemic mastocytosis.
iPlexusTM – The Intelligence Machine for Life Sciences. Try it now.
By Tapashi Mandal
Senior Research Analyst @ Innoplexus